SCHEMBL22173221

SCHEMBL22173221

O=C(Nc1ccc2[nH]c(=O)[nH]c2c1)c1ccccc1-c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.68
▸ TP53 P04637 1/20 0.60
▸ CHRNB2 P17787 1/20 0.60
▸ CHRNB4 P30926 1/20 0.60
▸ CHRNA3 P32297 1/20 0.60
▸ CHRNA4 P43681 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.56
▸ HTT P42858 2/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ KDM4E B2RXH2 6/20 0.56
▸ LMNA P02545 2/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ KLK7 P49862 1/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ GAA P10253 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20772457 0.90 MAPT (0.62) MAPTTP53CHRNB2CHRNB4CHRNA3
SCHEMBL30832878 0.90 MAPT (0.62) MAPTTP53CHRNB2CHRNB4CHRNA3
SCHEMBL18132580 0.85 MAPT (0.73) MAPTALDH1A1HTTL3MBTL1KDM4E
SCHEMBL20772536 0.85 MAPT (0.65) MAPTALDH1A1HTTL3MBTL1KDM4E
SCHEMBL30832805 0.82 ALDH1A1 (0.55) MAPTALDH1A1HTTL3MBTL1KDM4E
SCHEMBL20772671 0.80 MAPT (0.69) MAPTTP53ALDH1A1L3MBTL1KDM4E
SCHEMBL30625698 0.80 KDM4E (0.83) TP53CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL20777365 0.79 MAPT (0.68) MAPTALDH1A1HTTL3MBTL1KDM4E
SCHEMBL20777435 0.79 MAPT (0.64) MAPTALDH1A1HTTL3MBTL1KDM4E
SCHEMBL30832831 0.79 MAPT (0.64) MAPTALDH1A1HTTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MAPT 2761/4885TP53 42/4885CHRNB2 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback